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Abstract
Recessive dystrophic epidermolysis bullosa (RDEB) is caused by mutations in COL7A1
resulting in reduced or absent type VII collagen, aberrant anchoring fibril formation and sub-
sequent dermal-epidermal fragility. Here, we identify a significant decrease in PLOD3
expression and its encoded protein, the collagen modifying enzyme lysyl hydroxylase 3
(LH3), in RDEB. We show abundant LH3 localising to the basement membrane in normal
skin which is severely depleted in RDEB patient skin. We demonstrate expression is in-part
regulated by endogenous type VII collagen and that, in agreement with previous studies,
even small reductions in LH3 expression lead to significantly less secreted LH3 protein.
Exogenous type VII collagen did not alter LH3 expression in cultured RDEB keratinocytes
and we show that RDEB patients receiving bone marrow transplantation who demonstrate
significant increase in type VII collagen do not show increased levels of LH3 at the base-
ment membrane. Our data report a direct link between LH3 and endogenous type VII colla-
gen expression concluding that reduction of LH3 at the basement membrane in patients
with RDEB will likely have significant implications for disease progression and therapeutic
intervention.
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Introduction
Epidermolysis bullosa (EB) is a heterogeneous group of inherited disorders that can be either
localized within skin or systemic in presentation and severe cases are often life-threatening [1].
Technological and innovative approaches to therapies such as allogeneic cellular therapy [2,3],
gene therapy [4], and protein therapy [5] all offer substantial promise but current limitations
in both our understanding of each individual disease and the early stage of clinical develop-
ment suggest that several approaches are needed to be combined to realize a cure [6]. One par-
ticular sub-type of EB, RDEB, has garnered the lion’s share of therapeutic development due to
the devastating phenotype [7]. A wide variety of loss-of-function mutations in the gene encod-
ing type VII collagen, COL7A1, cause RDEB [8] and lead to a spectrum of severity encompass-
ing skin blistering with mucosal involvement, extensive scarring in response to wound healing,
nail dystrophy, alopecia, mitten deformities of the hands and feet, and a significant risk of
developing life threatening skin cancer [9].
Bone marrow transplantation is currently the only systemic novel therapy for treating
RDEB and recent trials demonstrate clinical benefit for the majority of patients who success-
fully tolerate immunomyeloablative chemotherapy and allogeneic stem-cell transplantation
[2]. However, this study demonstrated that although increased type VII collagen is evident in
patient skin after transplantation, anchoring fibrils (the major structural component resulting
from type VII collagen processing) are absent some 100 days post procedure [2] suggesting
that the mere presence of increased type VII collagen was insufficient to recapitulate the ultra-
structural features of fully functional skin in RDEB patients receiving therapy. This indicates
that further refinements to the procedure or additional interventions are required for a com-
plete cure.
Integrity of epithelia relies on multi-protein adhesion complexes that secure intracellular
components to underlying tissue. In skin this is achieved by interactions between the basal ker-
atinocyte cytoskeleton, hemidesmosome complexes at the dermal-epidermal junction and the
underlying anchoring fibrils. Anchoring fibrils are supramolecular structures primarily com-
posed of type VII collagen [10] that originate and terminate within the basement membrane
[11] tethering this superstructure to collagen bundles within the dermis [12]. Synthesis and
processing of mature collagen molecules involves many post-translational modifications that
ensure correct intramolecular association between three polypeptide chains as well as intermo-
lecular interaction between collagens of the same and different species dependent on tissue and
functional context (for review see [13]). Type VII collagen is first organized as a homotrimer
[14] within the cell which is subsequently secreted and cleaved at the C-terminal domain to
yield antiparallel dimers which are in turn bundled together to form anchoring fibrils [15].
Other post-translational modification and processing events that lead to mature anchoring
fibril formation have yet to be reported but as type VII collagen retains structural attributes
present in all collagens it can be assumed common enzymatic modification pathways exist
[16]. The central collagenous domain follows a classical Gly-X-Y repeat sequence where amino
acids at position Y are frequently modified through a variety of enzymatic processes necessary
for proper function. Hydroxylation and subsequent glycosylation of lysine residues at position
Y is emerging as an essential post-translational modification (reviewed in [17]) as evidenced by
lethality of knockout mice [18–20] and human diseases associated with mutation in the
enzymes which catalyze this reaction, lysyl hydroxylase (LH) [21–23]. Different LH isoforms
exist; LH1, LH2a, LH2b and LH3, but only LH3 has the ability to glycosylate hydroxylysine res-
idues and is the only LH to be secreted and present in the extracellular space [24–26]. Reduc-
tion of LH3 causes deleterious changes to the deposition and organization of extracellular
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matrix in skin and from skin derived fibroblasts [27]. Here, we identify a significant reduction
of LH3 in RDEB skin and investigate the relationship between LH3 and type VII collagen.
Results
Lysyl hydroxylase 3 localizes to epidermal basement membrane and is
reduced in patients with recessive dystrophic epidermolysis bullosa
To investigate a link between the altered dermal architecture in RDEB [28,29] and a reduction
of the essential collagen modifying enzyme lysyl hydroxylase 3 (LH3), we followed up our pre-
vious gene expression profiling of cultured keratinocytes [30] that shows PLOD3 (encoding
LH3) is significantly reduced in RDEB (S1 Table). Antibodies raised against LH3 revealed strik-
ing localization to the dermal-epidermal junction in normal skin which was significantly
reduced in RDEB patients (Fig 1A). Similarly, a reduction in LH3 localization at the basement
membrane is also evident in COL7A1 -/- epidermis isolated from a humanized murine model
of RDEB (Fig 1B; for details on creation of this novel RDEB model see S1–S3 Figs). The reduc-
tion in expression of PLOD3 and LH3 was confirmed in human keratinocytes derived from
RDEB patients by Q-PCR (panel a in S4 Fig) and western blotting of both total cell lysate and
secreted proteins using antibodies raised against LH3 (Fig 1C). Although gene expression anal-
ysis of cultured fibroblasts did not reveal changes between RDEB and non-RDEB fibroblasts at
the level of mRNA ([28]; panel b in S4 Fig), western blotting identified a depletion of secreted
Fig 1. LH3 localizes to the basement membrane and is reduced in RDEB. (a) LH3 immunohistochemistry reveals bright linear reactivity at the basement
membrane in normal skin (top left panel) which is discontinuous and greatly reduced in RDEB skin. Graph shows morphometric quantification of LH3 signal
intensity, +/- standard deviation. * = p < 0.01, ** = p < 0.0005, students-T test. (b) Type VII collagen immunohistochemistry shows bright linear reactivity at
the basement membrane in COL7A1 +/- newborn murine skin (+/- C7, top left panel) which is absent in COL7A1 -/- newborn murine skin (bottom left panel).
LH3 immunohistochemistry shows bright linear reactivity at the basement membrane inCOL7A1 +/- murine skin (top right panel) which is reduced in
COL7A1 -/- murine skin (bottom right panel). (c) LH3 protein is reduced in cell extracts and significantly reduced in conditioned media from RDEB
keratinocytes (RDEB1K, RDEB14K and RDEB2K) compared with normal keratinocytes (NHK, K16 and K17). (d) Fibroblast cultures isolated from RDEB
patients express significantly less LH3 compared with cultures of normal fibroblasts (NHF). Graphs show average densitometry of LH3 protein normalized to
GAPDH (using ImageJ version 1.48, imagej.nih.gov/ij/) for RDEB or normal controls. p values calculated using student-T test and error bars show +/-
standard deviation.
doi:10.1371/journal.pone.0137639.g001
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LH3 from RDEB fibroblasts (Fig 1D). Overall these data show a significant reduction in LH3
secretion in RDEB in vivo and in vitro.
Lysyl hydroxylase 3 interacts with type VII collagen in vivo and co-
localizes with the central collagenous domain of type VII collagen by
postembedding immunoelectron microscopy
In agreement with a recent report using stable isotope labeling by amino acids in cell culture
(SILAC) analyses of affinity-purified type VII collagen complexes [31] we show an interaction
between LH3 and type VII collagen in vitro by immunoprecipitation and western blotting (Fig
2A). Type VII collagen immunoprecipitates from RDEB keratinocytes retrovirally transduced
with COL7A1 showed clear reactivity for LH3 when immunoblotted with an LH3 specific anti-
body (Fig 2A). In situ proximity ligation assay (PLA) confirmed a direct interaction between
LH3 and type VII collagen at the basement membrane in vivo in normal skin which was
reduced or absent in RDEB skin (Fig 2B). PLA with antibodies against LH3 and another base-
ment membrane component, the γ2-chain of laminin 332, did not show similar reactivity. Co-
localization was apparent using dual immunofluorescence (IF) with antibodies raised against
type VII collagen and LH3, and the data also suggests a direct relationship between the amount
of type VII collagen immunoreactivity and LH immunoreactivity at the basement membrane
(not shown). Postembedding immunoelectron microscopy and localization morphometric
measurement of antibodies raised against the N and C termini of type VII collagen as well as
the C-terminus of LH3 demonstrated immunogold labeling beneath epidermal tissue where
LH3 was localized to two main places; over the lamina densa/basement membrane beneath
hemidesmosomes and in the sub-lamina densa region in an overlapping distribution close to
anchoring fibrils (Fig 2C; for antibody details see Table 1). There were statistically significant
differences (P<0.01) observed between the depth of the two LH3 epitopes and both type VII
collagen epitopes suggesting that LH3 co-localizes with the central collagenous domain of type
VII collagen in vivo (Fig 2C).
Endogenous type VII collagen regulates LH3 expression in RDEB
keratinocytes
Next, we analyzed the association between C7 expression and LH3 by looking at whether type
VII collagen could influence levels of LH3 expression. Using viral mediated over-expression we
show that full length type VII collagen increases LH3 expression in RDEB keratinocytes (Fig
3A and 3B). siRNA knockdown of either endogenous (Fig 3C) or virally expressed COL7A1
(not shown) concomitantly led to reduced LH3 expression and secretion. A reciprocal relation-
ship was not evident as PLOD3 siRNA knockdown did not affect type VII collagen levels (S5
Fig). To determine whether LH3 expression correlates with endogenous or exogenous type VII
collagen in RDEB keratinocytes we cultured cells in the presence of matrix or conditioned
media derived from type VII collagen over-expressing cells and saw no change in LH3 levels
(Fig 3D and 3E).
Bone marrow transplantation increases type VII collagen but does not
change LH3 at the basement membrane in RDEB patients
The above data demonstrates that endogenous type VII collagen regulates LH3 expression and
suggests that therapies designed to deliver type VII collagen to RDEB patients will not alter
LH3 levels unless a significant proportion of cells within the patient endogenously express type
VII collagen. Therefore, in order to determine whether this is the case we assessed expression
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of LH3 in RDEB patients after bone marrow transplantation where it has been demonstrated
in animal studies that a small number (0.5%) of donor bone marrow-derived cells home to skin
wounds and secrete type VII collagen [32]. We used IF and morphometric quantification to
determine the extent of immunoreactivity to LH3 specific and type VII collagen specific anti-
bodies at the basement membrane of patient skin. Although type VII collagen was significantly
increased as a result of transplantation, LH3 levels remained constant (Fig 4) indicating that
indeed, in patients with exogenous type VII collagen delivery, LH3 levels did not increase.
Fig 2. Type VII collagen binds LH3 in vitro and in vivo at the basement membrane in normal skin. (a) LH3 interacts with type VII collagen (C7) in vitro.
Cell extracts from RDEB keratinocytes retrovirally expressing COL7A1 were immunoprecipitated (IP) with a C7 antibody (lane 1) and immunoblotted for LH3
co-precipitation. Controls include a non-specific IgG (lane 2), protein G beads alone (no antibody, lane 3) or C7 IP in COL7A1 null keratinocyte extracts (lane
4). Lanes 5 and 6 represent the inputs from COL7A1 expressing and null keratinocyte extracts respectively. (b) Proximity Ligation Assay demonstrates the
close interaction of antibodies raised against LH3 and type VII collagen in vivo at the basement membrane in normal skin (top left panel, red signal) which is
greatly reduced or absent in RDEB skin, with LH3 antibody only or with antibodies against LH3 and LN332 γ-2 chain. (c) Postembedding immunoelectron
microscopy of human skin shows immunogold labeling beneath epidermal tissue using the LH7.2 mouse monoclonal antibody that recognizes the type VII
collagen C-terminus (C7, upper panel, 5nm particles, arrowheads). LH3 polyclonal antisera (LH3, lower panel, 10nm particles, white arrows) localized
beneath the epidermal tissue in an overlapping distribution close to anchoring fibrils (arrowheads, lower panel). Graph shows morphometric analysis of
distance from plasmamembrane (indicated by *) of immunogold particles. There were statistically significant differences (p < 0.01) observed between the
depth of the two PLOD3 epitopes and both collagen VII epitopes. LH3/PLOD3 R = rabbit polyclonal antibody, M = mouse monoclonal antibody.
doi:10.1371/journal.pone.0137639.g002
LH3 Is Reduced in Patients with RDEB
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Discussion
Our results reveal a collagen modifying enzyme which is essential for proper basement mem-
brane formation [19] and extracellular matrix organization [27], is present at the basement
membrane in skin and is significantly reduced in patients with RDEB (Figs 1 and 4). The data
are consistent with a reduction in secreted LH3 in response to reduced or absent endogenous
Table 1. Antibodies used in immunoelectron microscopy.
Clone or antibody name Antigen or epitope
recognized
Species and
Immunoglobulin subtype
Dilution Number of gold
particles examined
Reference
Collagen VII LH7.2 CollagenVII N-terminal Mouse IgG 1 in 10 294 [43]
CollagenVII NC-2domain CollagenVII C-terminal Rabbit polyclonal 1 in 200 253 [11]
LH3/PLOD3 (M) Mouse
monoclonal 60058-1-Ig
LH3/PLOD3 antibody Mouse IgG2a 1 in 10 207 Proteintech Group,
Chicago, IL
LH3/PLOD3 (R) Rabbit
polyclonal 11027-1-AP
LH3/PLOD3 antibody N-
terminal
Rabbit polyclonal 1 in 20 250 Proteintech Group,
Chicago, IL
Rabbit polyclonal pre-immune
serum
Pre immune Rabbit 1 in 200 No BMZ signiﬁcant /
speciﬁc labeling
[11]
NS0 myeloma cell line
supernatant
None Mouse IgG neat No BMZ signiﬁcant /
speciﬁc labeling
AbD Serotec,
Raleigh, NC
Anti-human HLA MHC class I
MCA485
Anti-human HLA MHC
class I antibody
Mouse IgG 1 in 20 No BMZ signiﬁcant /
speciﬁc labeling
AbD Serotec,
Raleigh, NC
doi:10.1371/journal.pone.0137639.t001
Fig 3. Endogenous but not exogenous type VII collagen increases LH3 expression in RDEB keratinocytes. (a) Retroviral delivery of type VII collagen
in RDEB14 keratinocytes increases LH3 expression by immunofluorescence. (b) Type VII collagen increases LH3 in RDEB14 keratinocytes in cell extracts
and conditioned media by immunoblotting. (c) siRNA depletion of COL7A1 reduces LH3 expression in normal keratinocytes compared with non-targeting
control (NT). (d) RDEB14 keratinocytes grown in conditioned media collected from RDEB14 keratinocytes overexpressing type VII collagen do not have
increased LH3 expression compared with conditioned media collected from RDEB14 keratinocyte empty vector controls. (e) RDEB14 keratinocytes grown
on cell matrix derived from type VII collagen overexpressing RDEB14 keratinocytes do not show increased LH3 expression compared with empty vector
control treated cells. Empty Vector or EV = empty vector cells, C7A1 = COL7A1 over expressing cells.
doi:10.1371/journal.pone.0137639.g003
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type VII collagen (Figs 1–4). Given the reported importance of LH3 in deposition and organi-
zation of extracellular matrix [27] and that LH3 modifies proteins in the extracellular space
[24], reduction of LH3 likely contributes to the altered dermal microenvironment composition
observed in RDEB and in response to type VII collagen depletion in normal fibroblasts
[28,29,33]. In this respect it is important to note that two studies by Kuttner and colleagues
using a proteomics approach identified that LH3 was increased in RDEB fibroblasts [29,31].
We attribute the observed differences in LH3 expression to a combination of different analyti-
cal approaches, initial culture densities and timing of isolation. We also note that although cul-
tured cells are an excellent model of human skin they themselves have limitations even though
the significant reduction of LH3 in RDEB skin in vivo is supported by our in vitro studies.
Indeed, the recent proteomic approach [31] identified a reduction in type IV collagen which
was not altered in our cohort of RDEB patients in vitro or in vivo (not shown). This observation
is well established as type IV collagen is reported to be unchanged in RDEB skin by numerous,
independent studies utilizing type IV collagen antibodies as a diagnostic tool [34–36]. Further-
more, the lack of difference in type IV collagen expression in RDEB rules out a link between
this basement membrane associated collagen and LH3 in RDEB, which might be implied by
the observation that mice lacking LH3 fail to develop correct basement membrane as a result of
impaired type IV collagen secretion [18]. Here, we show that reduction of LH3 in RDEB is a
result of reduction or absence of type VII collagen, rather than alterations in type IV collagen.
One deficiency of our study is that we do not demonstrate a direct functional link between
reduced LH3 levels in RDEB and the impact this may have on the altered dermal microenvi-
ronment observed in patient skin. We are pursuing this aspect as part of a larger study dissect-
ing the role of extracellular LH3 in skin, work which is beyond the scope of the current
investigation. However, given the direct relationship between LH3 levels and glycosylation
activity in murine organs [24] we expect a similar relationship to exist in human skin and that
Fig 4. Bonemarrow transplantation increases type VII collagen but does not change LH3 at the basement membrane in RDEB patients. (a) LH3
immunoreactivity (red) does not change after bone marrow transplantation in two RDEB patients. (b) Type VII collagen expression (green) is increased after
bone marrow transplantation. d = day, yr = year. Graph shows morphometric quantification of LH3 and type VII collagen signal intensities, +/- standard
deviation. * = p < 0.001, ** = p < 0.0001, *** = p < 0.00001, students-T test.
doi:10.1371/journal.pone.0137639.g004
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a reduced level of activity in RDEB will have similar consequences to those described in experi-
mental settings. Consistent with multiple mechanisms regulating LH3 expression and secre-
tion, two secretory pathways have been reported; a higher molecular weight N-glycosylated
form of LH3 is secreted via the ER/Golgi pathway into the extracellular space and serum, while
LH3 found at the cell surface appears to bypass processing in the Golgi [26]. We have con-
firmed that both keratinocytes and fibroblasts isolated from skin secrete the higher molecular
weight N-glycosylated form (not shown). Our observations of reduced LH3 in RDEB is intrigu-
ing, especially in light of our findings that LH3 interacts with type VII collagen at the epidermal
basement membrane (Fig 2). Glycosyltransferase activity and cellular secretion is specific to
LH3 and the latter is reported to be dependent on the former [26]. Given the importance of gly-
cosylated hydroxylysines in collagen IV tetramerization [37]) and the demonstration that LH3
glucosylation activity within the collagenous domain of adiponectin is essential for its oligo-
merization [38], it would follow that LH3 has a crucial role in the formation of anchoring fibrils
through its modification of type VII collagen, a potential substrate of LH3. Certainly, this
would fit with the observation that LH3 glycosyltransferase activity is essential for basement
membrane formation [19] and the absence of mature anchoring fibrils in patients receiving
bone marrow transplantation [2]. Again, these aspects are being pursued as a separate, larger
study.
A number of disease modifiers in RDEB have been proposed [39–41] and although no single
pathway has been replicated in multiple patient cohorts [42] it is clear there is significant phe-
notypic diversity between members of the same family with identical COL7A1mutations. It is
therefore tempting to speculate that polymorphisms in the PLOD3 gene which result in
reduced expression or activity may well be a disease modifier. Further work will be needed to
confirm this but it is interesting to note that although LH3 levels were consistently low in
RDEB cells in culture there was considerable variation between patients (Fig 1).
Finally, our observations that LH3 levels do not change after bone marrow transplantation
even when an increase in type VII collagen is evident (Fig 4) raises important questions. Firstly,
although murine data demonstrate that full length type VII collagen can be secreted and cor-
rectly processed by donor marrow cells after transplantation, it has not been proven that the
increase in type VII collagen in human RDEB patient skin after transplantation is a result of
donor marrow cells or represents an increase in patients own type VII collagen, as has been
suggested for other trials involving allogenic cell transfer [3]. Such a scenario might suggest
that full length, correctly processed type VII collagen is required for increased LH3 expression,
whereas if the increased type VII collagen derives from a small number of donor marrow cells
this might suggest that although type VII collagen is able to home to the basement membrane
zone, as has been demonstrated after injection of recombinant type VII collagen protein [5],
the overall number of donor cells does not impact the expression and secretion of LH3 from
the patients own cells. Further work is required to determine whether PLOD3 expression and/
or LH3 secretion can be enhanced pharmacologically and whether this will have any additional
clinical benefit to RDEB patients receiving type VII collagen-based therapies.
Materials and Methods
Skin tissue
Samples were obtained after informed, written consent, and were from unremarkable skin
from a non-specialized site obtained after routine surgical or diagnostic procedures. This study
has been approved by the appropriate research ethics committees (University of Minnesota
IRB 0911M74035; UKMREC 05/Q0603/9; The Royal Children’s Hospital and Health Services
LH3 Is Reduced in Patients with RDEB
PLOSONE | DOI:10.1371/journal.pone.0137639 September 18, 2015 8 / 15
District Human Research Ethics Committee (2008/111), University of Queensland) and in
accordance with the Helsinki declaration.
Antibodies
The antibodies used in this study were: mouse monoclonal LH7:2 used at 1:2 dilution as
described for IEM [43] and 1:800 for proximity ligation assay (PLA); Rabbit polyclonal antisera
to type VII collagen raised against the NC1 domain (Moravian Biotechnology, Brno, Czech
Republic); mouse monoclonal antibody against type VII collagen #611607 (lot 01591 30625)
1:200 dilution used for IF (BD Biosciences, San Jose, CA); PLOD3 (11027-1-AP, Lot 00001261)
rabbit polyclonal used at 1:5 dilution for IEM and 1:10–20 for IMF (ProteinTech Group, Chi-
cago Ill, USA); PLOD3 (60058-1-Ig) mouse monoclonal used at 1:500 dilution for Western
blot (ProteinTech Group); Laminin-332 (γ2 chain) mouse monoclonal (MAB19562, Millipore,
Billerica, MA); GAPDHmouse monoclonal (G8795, Sigma Aldrich, Dorset, UK); Actin mouse
monoclonal (Abcam, ab8226); normal rabbit IgG (12–370, Millipore, Billerica, MA).
Immunofluorescence (IF)
RDEB and human control skin biopsies were frozen in optimal cutting temperature (OCT,
Sakura Finetek USA, Torrance, CA) and cut at 6 microns on a cryostat. Sections were fixed
with 50:50 methanol: acetone mixture for 5 minutes. Slides were rinsed with 1x PBS, permeabi-
lized with PBS/0.1% Tween 20 (Sigma Aldrich, St. Louis, MO) for 5 minutes followed by block-
ing for 1 hour with PBST/3% BSA (Sigma Aldrich, St. Louis, MO). Primary antibodies were
incubated for 1.5 hours at room temperature. Secondary antibodies donkey anti-rabbit cy3
(1:500, Jackson Immunoresearch, West Grove, PA), and Alexa Fluor 488 goat anti-mouse
(1:1000, Molecular Probes Eugene, OR) were applied for 1 hour at room temperature. Slides
were cover-slipped with hard set 4,6-diamidino-2-phenylindole (DAPI; Vector Labs, Burlin-
game, CA) and examined by confocal fluorescence microscopy (Olympus BX61, Olympus
Optical, Tokyo, Japan).
IF Quantification
Single color images were converted to grayscale and a grid was applied using Adobe1 Photo-
shop C6 (Adobe Systems Incorporated, San Jose, CA). A uniform area was centered on the
basement membrane at every intersection with the grid and pixel density was measured.
Generation of a humanized mouse model of recessive dystrophic
epidermolysis bullosa based on the common R578X nonsense mutation
In order to carry out preclinical testing to readthrough agents in the context of RDEB (Gartner
U, Warbrick E and McLean WHI, unpublished) we generated a humanized mouse model
where the human COL7A1 cDNA carrying the commonly reported R578X nonsense mutation
[44] was knocked into the murine Col7a1 locus by gene targeting in embryonic stem (ES) cells.
Mouse generation was done under licence by TaconicArtemis GmbH, Cologne, Germany,
using the gene targeting strategy as detailed in S1 Fig. The targeted allele included a small num-
ber of introns to improve expression in vivo and to help model nonsense mediated mRNA
decay, a known feature of the human disease. Other than the R578X nonsense mutation (S1
Fig), no other changes were made to the human collagen VII coding sequence. Double selection
of correctly targeted ES cell clones was performed, making use of a neomycin resistance cas-
sette placed in intron 64 of the human gene as well as a puromycin resistance cassette placed
immediately downstream of the human cDNA construct (Panels c and d in S1 Fig). Correct
LH3 Is Reduced in Patients with RDEB
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gene targeting was confirmed by a number of PCRs specific for the junctions of the targeted
allele (not shown). Following generation of mice carrying the targeted allele shown in panel c
of S1 Fig, both selection markers were removed by crossing to mice universally expressing Flp
recombinase under control of the chicken-beta-actin promoter, to generate mice with the final
humanized allele shown in panel d in S1 Fig.
Crossing of heterozygous humanized COL7A1mice gave the expected Mendelian ratios of
wild-type, heterozygous and homozygous offspring. Wild-type and heterozygous littermates
had no discernable phenotype, however, homozygous animals developed skin blistering, which
was especially obvious on the forepaws, although blisters were also observed on other sites (S2
Fig). Histological examination of the skin of homozygous mice revealed blistering in the upper
papillary dermis leading to complete sloughing off of the overlying epidermis (S3 Fig),
completely mirroring the skin fragility observed in RDEB patients. Thus, these mice develop
skin blistering that resembles both the human disease and the well-characterised COL7A1
knockout mouse [45]. These animals are a suitable model for preclinical testing of new classes
of drugs that act through suppression of nonsense mutations.
Cells
S2 Table details all cells used in this study. Primary keratinocytes were isolated from fresh
RDEB or healthy skin and cultured as previously described [30]. HpV immortalized cell lines
have been described previously [46,47].
Immunoblotting
Whole cell extracts were collected using radioimmunoprecipitation assay (RIPA) buffer and
protein concentration determined by the Bradford Assay (Sigma Aldrich). Proteins were sepa-
rated by electrophoresis using either NuPAGE 4–12% Bis-tris gels (Life Technologies, Paisley,
UK) or 4–20% mini-PROTEAN TGX gels (Bio-Rad, Hertfordshire, UK) for type VII collagen.
Protein was transferred to a nitrocellulose membrane using the Trans-Blot Turbo system (Bio-
Rad). For conditioned media experiments 5x106 cells were seeded per 100mm cell culture dish
and allowed to adhere overnight in keratinocyte media containing serum. Cells were washed
twice with PBS and 15ml keratinocyte media without serum added for 48 hours. Media was
then transferred to a pre-chilled 50ml Falcon tube, spun at 1200rpm for 5 minutes to remove
debris then concentrated to 200μl at 3200rpm at 4°C in an Amicon Ultra-15 Centrifugal filter
unit with 10K cutoff (Millipore, Billerica, MA). Cells remaining on the plate were harvested in
RIPA buffer as above and the volume of conditioned media loaded onto the gel normalized to
the total protein amount from whole cell extracts.
Co-immunoprecipitation
Protein extraction and co-immunoprecipitation were performed using the Universal Magnetic
Co-IP kit (Active Motif, Rixensart, Belgium) according to manufacturer’s instructions. Briefly,
cells were grown to confluence, proteins were extracted using whole cell lysis buffer and 200μg
lysate incubated with either 1μl rabbit polyclonal sera to type VII collagen or a normal rabbit
IgG control antibody (Millipore) for 2 hours at 4°C on a rotator. Protein G magnetic beads
were then added for 1 hour at 4°C on a rotator and immune-complexes collected in 20μl 2x
Laemmli buffer (+100mM DTT) after 5 washes in Co-IP wash buffer. 10μl sample was loaded
per lane of a 4–20% mini-PROTEAN TGX gel (Bio-Rad) and western blotting performed as
described above with antibodies to LH3 (mouse monoclonal, ProteinTech Group) and type VII
collagen.
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Immunogold electron microscopy (IEM)
Normal human skin samples were processed for post-embedding immunoelectron microscopy
as previously described [11,48]. Briefly, cryofixed, cryosubstituted samples were embedded in
Lowicryl K11M resin and polymerized at -60°C under UV light. Selected blocks were used to
produce ultrathin sections that were incubated with antibodies (80 μg/ml) diluted in PBS-
based buffer and washed four times (5 minutes each). Further incubations were performed
using rabbit anti-mouse and goat anti rabbit antibodies at 1 in 500 in PBS based buffer [11] fol-
lowed by four washes and further incubation with either 5 or 15 nm gold-conjugated antibody
for immunogold labeling (Biocell, Cardiff, UK) diluted 1 in 200 in Tris Buffered Saline. LH7:2
antibody which recognizes the N-terminal domain of human collagen VII [43] was included
for comparison. Sections were viewed under a Hitachi H-7100 or Jeol 1010 transmission elec-
tron microscope (Hitachi, Jeol Tokyo, Japan) at 80 KV.
Immunogold distribution assessment
The techniques for ultrastructural measurements were almost identical to those performed pre-
viously [11] using normal control human skin as the labeling substrate. Electron micrographs
were taken at a standard magnification and enlarged by a standard factor. The final magnifica-
tion was checked using electron micrographs taken of a carbon diffraction grating. For the pur-
poses of standardization all measurements were made by one observer (JRM). All
measurements were in nanometers (nm) from the plasma membrane (values were positive for
measurements below the plasma membrane and negative for above the plasma membrane).
The number of gold particles measured was between 200 and 300 (minimum 207 particles) for
each antibody or antiserum (Table 1). Approximately 20 individual micrographs covering
more than 40 μm of basement membrane were scanned and gold particle analysis performed
for each epitope. Each antibody was labeled in duplicate using skin samples from two different
individuals, and the data checked for any difference and then pooled. Control supernatant,
pre-immune sera and an irrelevant isotype controlled (HLA) antibody were included as nega-
tive controls. Only non-obliquely (perpendicular) sectioned areas of basement membrane zone
were included in the analysis with clearly defined lamina lucida and lamina densa. The dermal-
epidermal junction beneath melanocytes or damaged areas was excluded. The distance from
the plasma membrane to the center of each gold particle was measured and recorded. Very lit-
tle gold labeling was localized further than 350nm from the plasma membrane zone. Gold par-
ticles that appeared to be to be clumped or associated with any stain-deposit were excluded
from the analysis.
Proximity Ligation Assay
Frozen skin sections were prepared as described above and protein interactions visualized by
immunofluorescence using Duolink in situ PLA technology (Olink Bioscience, Uppsala, Swe-
den). Sections were blocked for 2 hours in 3% BSA/PBS then incubated with antibodies to LH3
(rabbit polyclonal, 1:10 dilution) and type VII collagen (mouse LH7.2, 1:800 dilution) over-
night at 4°C. After washing, the slides were incubated with Duolink PLA Rabbit MINUS and
PLAMouse PLUS proximity probes (Olink Bioscience) at a 1:5 dilution at 37°C for 2 hours.
Proximity ligation was then performed using the Duolink detection reagent kit (Olink Biosci-
ence) according to manufacturer’s instructions except for the amplification step which was per-
formed for 2 hours at 37°C. Slides were mounted using ProLong Gold Antifade with DAPI
(Life Technologies, Paisley, UK) and imaged on the Zeiss Axioskop 2 fluorescent microscope
using AxioVision Rel. 4.7 software (Carl Zeiss, GmbH, Jena, Germany).
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Retroviral transduction and siRNA transfection
COL7A1 overexpression and siRNA knockdown were performed as described previously [46].
Quantitative real time-PCR
cDNA was prepared from RNA isolated using RNA-Bee (AMS Biotechnology, Abingdon-on–
Thames, UK) and the QuantiTect reverse transcription kit (Qiagen, Manchester, UK). For
quantitative measurement of mRNA the QuantiTect SYBR Green PCR kit (Qiagen) was used
with following primers: PLOD3 forward (5’-CAGCTCCAGGACCACTTCTC-3’) and reverse
(5’-ATGAGGATACGCAGGGTCTG-3’) and GAPDH forward (5’-TCCGGGAAACTGTGG
CGTGA-3’) and reverse (5’-ACGGAAGGCCATGCCAGTGA-3’). PCR samples were set up
on the QIAgility automated PCR workstation and reactions performed on the Rotor-Gene Q
(Qiagen). Relative expression was calculated using the ΔΔCT method.
Cell derived matrix and type VII collagen conditioned media incubation
The cell derived matrix experiment was performed essentially as described previously [46]. For
incubation with type VII collagen conditioned medium, keratinocytes retrovirally transduced
with COL7A1 or the empty pBabe vector were seeded at 5x106 cells per 100mm dish in kerati-
nocyte medium plus serum. The next day the cells were washed twice with PBS and 15ml
serum free keratinocyte medium containing 0.1 mmol/L l-ascorbic acid 2-phosphate (A8960;
Sigma-Aldrich) was added for 48 hours. Media was concentrated, as detailed above, down to
1ml. Conditioned media was added to COL7A1 null keratinocytes seeded in a 6 well plate and
made up to a final volume of 3ml/well with fresh media. Cells were incubated for 48 hours at
37°C before protein extraction and analysis by western blot.
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